Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells

NeuroToxicology

Volumn 23, Issue 4-5, 2002, Pages 569-580

  Stephans, Stacy E ^a   Miller, Gary W ^a   Levey, Allan I ^a   Greenamyre, J Timothy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DAT; Mitochondria; Monoamine; MPP+; Neurotoxicity; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; DOPAMINE TRANSPORTER; ROTENONE; TETRAPHENYLPHOSPHONIUM; CARRIER PROTEIN; CATION; COLORING AGENT; MEMBRANE PROTEIN; NERVE PROTEIN; ORGANOPHOSPHORUS COMPOUND; SLC6A3 PROTEIN, HUMAN;

APOPTOSIS; CELL DEATH; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOCHONDRION; NEUROBLASTOMA CELL; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; PROTON TRANSPORT; TIME SERIES ANALYSIS; ARTICLE; BIOSYNTHESIS; BRAIN TUMOR; CELL CULTURE; DRUG EFFECT; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NEUROBLASTOMA; PATHOLOGY; WESTERN BLOTTING;

1-METHYL-4-PHENYLPYRIDINIUM; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL DEATH; COLORING AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MITOCHONDRIA; NERVE TISSUE PROTEINS; NEUROBLASTOMA; ONIUM COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036777178     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(02)00060-8     Document Type: Conference Paper

References (47)

1. Blandini F, Nappi G, Greenamyre JT. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann Neurol 2001;49:525-9.
2. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-50.
3. +-induced apoptosis depends on mitochondrial membrane potential and ATP synthase. Biochem Biophys Res Commun 1999;257:440-7.
4. Chiba K, Trevor A, Castagnoli Jr, N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984;120:574-8.
5. +, oxidant and specific neurotoxicants shares the common molecular mechanism. J Neurochem 2001;76:1010-21.
6. Ciliax BJ, Heilman C, Demchyshyn LL, Pristupa ZB, Ince E, Hersch SM, Niznik HB, Levey AI. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1995;15:1714-23.
7. Cleeter MW, Cooper JM, Schapira AH. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 1992;58:786-9.
8. Davey GP, Tipton KF, Murphy MP. Uptake and accumulation of 1-methyl-4-phenylpyridinium by rat liver mitochondria measured using an ion-selective electrode. Biochem J 1992;288:439-43.
9. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997;69:1322-5.
10. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
11. Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, Beal MF. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced Parkinsonism in baboons. Nat Med 1996;2:1017-21.
12. Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984a;224:1451-3.
13. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984b;311:467-9.
14. 3H]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study. J Neurosci 1996;16:3807-16.
15. Hoek JB, Nicholls DG, Williamson JR. Determination of the mitochondrial protonmotive force in isolated hepatocytes. J Biol Chem 1980;255:1458-64.
16. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996;72:355-63.
17. +-induced toxicity: comparison between MN9D cells and CHO cells. Toxicol Lett 1999;11:49-56.
18. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-7.
19. +: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann Neurol 1992;32:109-11.
20. +) involves binding at the same site as the respiratory inhibitor, rotenone. Biochem Biophys Res Commun 1990;169:123-8.
21. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80.
22. Lotharius J, Dugan LL, O'Malley KL. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci 1999;19:1284-93.
23. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature 1984;311:464-7.
24. Melamed E, Rosenthal J, Cohen O, Globus M, Uzzan A. Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. Eur J Pharmacol 1985;116:179-81.
25. Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey AI. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 1997;41:530-9.
26. Miller GW, Kirby ML, Levey AI, Bloomquist JR. Heptachlor alters expression and function of dopamine transporters. Neurotoxicology 1999a;20:631-7.
27. Miller GW, Gainetdinov RR, Levey AI, Caron MG. Dopamine transporters and neuronal injury. Trends Pharmacol Sci 1999b;20:424-9.
28. Nakamura K, Bindokas VP, Marks JD, Wright DA, Frim DM, Miller RJ, Kang UJ. The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol Pharmacol 2000;58:271-8.
29. Nicholls D, Akerman K. Mitochondrial calcium transport. Biochim Biophys Acta 1982;683:57-88.
30. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985;36:2503-8.
31. Owicki JC, Bousse LJ, Hafeman DG, Kirk GL, Olson JD, Wada HG, Parce JW. The light-addressable potentiometric sensor: principles and biological applications. Annu Rev Biophys Biomol Struct 1994;23:87-113.
32. Pifl C, Giros B, Caron MG. Dopamine transporter expression confers cytotoxicity to low doses of the Parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 1993;13:4246-53.
33. Raley-Susman KM, Miller KR, Owicki JC, Sapolsky RM. Effects of excitotoxin exposure on metabolic rate of primary hippocampal cultures: application of silicon microphysiometry to neurobiology. J Neurosci 1992;12:773-80.
34. Ramsay RR, Salach JI, Dadgar J, Singer TP. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic Parkinsonism. Biochem Biophys Res Commun 1986;135:269-75.
35. Saporito MS, Heikkila RE, Youngster SK, Nicklas WJ, Geller HM. Dopaminergic neurotoxicity of 1-methyl-4-phenylpyridinium analogs in cultured neurons: relationship to the dopamine uptake system and inhibition of mitochondrial respiration. J Pharmacol Exp Ther 1992;260:1400-9.
36. Sherer TB, Betarbet R, Lund S, Kuwajima M, Greenamyre JT. An in vitro model of Parkinson's disease: chronic complex I inhibition. Soc Neurosci Abst 2000;26:241-80.
37. Shimada S, Kitayama S, Walther D, Uhl G. Dopamine transporter mRNA: dense expression in ventral midbrain neurons. Ann Neurol 1992;13:359-62.
38. Singer TP, Ramsay RR. The reaction sites of rotenone and ubiquinone with mitochondrial NADH dehydrogenase. Biochim Biophys Acta 1994;118:192-202.
39. +-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport 1994;5:2598-600.
40. + inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). Exp Cell Res 1999;250:75-85.
41. Song X, Perkins S, Jortner BS, Ehrich M. Cytotoxic effects of MPTP on SH-SY5Y human neuroblastoma cells. Neurotoxicology 1997;18:341-53.
42. Storey E, Hyman BT, Jenkins B, Brouillet E, Miller JM, Rosen BR, Beal MF. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 1992;58:1975-8.
43. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991;349:414-8.
44. Uhl GR. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 1998;43:555-60.
45. Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF, Anderson JK. Caspase-9 activation results in downstream caspase-8 activation and Bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci 2001;21:9519-28.
46. Vyas I, Heikkila RE, Nicklas WJ. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem 1986;46:1501-7.
47. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in primates. J Neurochem 1992;59:733-9.